Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease Wiggelinkhuizen M; Tilanus ME; Bollen CW; Houwen RHAliment Pharmacol Ther 2009[May]; 29 (9): 947-58BACKGROUND: No consensus is available on the optimal initial treatment in Wilson disease. AIM: To assess systematically the available literature of treatment in newly presenting patients with a presymptomatic, hepatic or neurological presentation of Wilson disease. METHODS: A systematic literature search of the MEDLINE, EMBASE and COCHRANE databases was performed. Original studies on clinical efficacy of D-penicillamine, trientine, tetrathiomolybdate or zinc monotherapy as initial treatment in Wilson disease were included. A descriptive analysis of the relevant published data was performed. RESULTS: One randomized trial and 12 observational studies met the inclusion criteria. These studies were quite heterogeneous and generally of low validity. Nevertheless, according to currently available data, patients with hepatic presentation of Wilson disease are probably most effectively treated by D-penicillamine. Zinc seems to be preferred above d-penicillamine for treatment of presymptomatic and neurological patients, as in these subgroups, the tolerance profile is in favour of zinc, while no obvious differences in clinical efficacy could be observed. CONCLUSIONS: There is lack of high-quality evidence to estimate the relative treatment effects of the available drugs in Wilson disease. Therefore, multicentre prospective randomized controlled comparative trials are necessary.|Adolescent[MESH]|Adult[MESH]|Chelating Agents/*therapeutic use[MESH]|Child[MESH]|Child, Preschool[MESH]|Female[MESH]|Hepatolenticular Degeneration/*therapy[MESH]|Humans[MESH]|Infant[MESH]|Male[MESH]|Middle Aged[MESH]|Randomized Controlled Trials as Topic[MESH]|Trace Elements/*therapeutic use[MESH]|Treatment Outcome[MESH]|Young Adult[MESH]|Zinc/*therapeutic use[MESH] |
